WISP-1/CCN4 regulates osteogenesis by enhancing BMP-2 activity

Abstract

Wnt-induced secreted protein 1 (WISP-1/CCN4) is a member of the CCN family that is highly expressed in skeletal tissue and in osteoprogenitor cells induced to differentiate in vitro. To determine the function of WISP-1 during osteogeneis, osteogenic bone marrow stromal cells (BMSCs) were transduced with WISP-1 adenovirus (adWISP-1) in the presence or absence of bone morphogenetic protein 2 (BMP-2) adenovirus (adBMP-2). WISP-1 overexpression enhanced the ability of BMP-2 to direct BMSCs toward osteogenic differentiation and appeared to work by stimulating Smad-1/5/8 phosphorylation and activation. The ability of WISP-1 to enhance BMP-2 activity also was shown in vivo using an ectopic osteogenesis assay with BMSCs transduced with WISP-1, BMP-2, or both. When BMSCs were infected with lentivirus containing human WISP1 shRNA, they formed less bone in vivo and were less responsive to BMP-2, confirming that WISP-1 and BMP-2 have a functional interaction. Immunoprecipitation (IP) and Western blot analysis showed that WISP-1 bound directly to BMP-2 and showed that WISP-1 increased BMP-2 binding to hBMSCs in a dose-dependent fashion. To understand how WISP-1 enhanced BMP-2 signaling, the influence of WISP-1 on integrin expression was analyzed. WISP-1 induced the mRNA and protein levels of α5-integrin and, further, was found to bind to it. Antibody-blocking experiments showed that the BMP-2 binding to BMSCs that was enhanced by WISP-1 was completely neutralized by treatment with anti-integrin α5β1 antibody. Pilot studies and the use of transgenic mice that overexpressed human WISP-1 in preosteoblasts had increased bone mineral density (BMD), trabecular thickness, and bone volume (BV/TV) over wild-type controls, supporting observations using human osteoprogenitors that WISP-1 has a positive influence on osteogenesis in vivo. In conclusion, these studies show, for the first time, that WISP-1 has a positive influence on bone cell differentiation and function and may work by enhancing the effects of BMP-2 to increase osteogenesis through a mechanism potentially involving binding to integrin α5β1. © 2011 American Society for Bone and Mineral Research.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 79

1. 1.

   Parisi MS, Gazzerro E, Rydziel S, Canalis E. Expression and regulation of CCN genes in murine osteoblasts. Bone. 2006;38:671-677.

   Not in our library10.1016/j.bone.2005.10.005

2. 2.

   French DM, Kaul RJ, D'Souza AL, et al. WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am J Pathol. 2004;165:855-867.

   Not in our library10.1016/s0002-9440(10)63348-2

3. 3.

   Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ. WISP1 is a Wnt-1- and β-catenin-responsive oncogene. Genes Dev. 2000;14:585-595.

   Not in our library

4. 4.

   Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 2009;13:485-496.

   Not in our library10.1517/14728220902841961

5. 5.

   Ling L, Nurcombe V, Cool SM. Wnt signaling controls the fate of mesenchymal stem cells. Gene. 2009;433:1-7.

   Not in our library10.1016/j.gene.2008.12.008

6. 6.

   Patel MS, Karsenty G. Regulation of bone formation and vision by LRP5. N Engl J Med. 2002;346:1572-1574.

   Not in our library10.1056/nejm200205163462011

7. 7.

   Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346:1513-1521.

   Not in our library10.1056/nejmoa013444

8. 8.

   Balemans W, Van Hul W. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology. 2007;148:2622-2629.

   Not in our library10.1210/en.2006-1352

9. 9.

   Blom AB, Brockbank SM, van Lent PL, et al. Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt-induced signaling protein 1. Arthritis Rheum. 2009;60:501-512.

   Not in our library10.1002/art.24247

10. 10.

    Geyer M, Grassel S, Straub RH, et al. Differential transcriptome analysis of intraarticular lesional vs intact cartilage reveals new candidate genes in osteoarthritis pathophysiology. Osteoarthritis Cartilage. 2009;17:328-335.

    Not in our library10.1016/j.joca.2008.07.010

11. 11.

    Inkson CA, Ono M, Kuznetsov SA, Fisher LW, Robey PG, Young MF. TGF-beta1 and WISP-1/CCN-4 can regulate each other's activity to cooperatively control osteoblast function. J Cell Biochem. 2008;104:1865-1878.

    Not in our library10.1002/jcb.21754

12. 12.

    Katsube K, Sakamoto K, Tamamura Y, Yamaguchi A. Role of CCN, a vertebrate specific gene family, in development. Dev Growth Differ. 2009;51:55-67.

    Not in our library10.1111/j.1440-169x.2009.01077.x

13. 13.

    Brigstock DR. The CCN family: a new stimulus package. J Endocrinol. 2003;178:169-175.

    Not in our library10.1677/joe.0.1780169

14. 14.

    Smerdel-Ramoya A, Zanotti S, Deregowski V, Canalis E. Connective tissue growth factor enhances osteoblastogenesis in vitro. J Biol Chem. 2008;283:22690-22699.

    Not in our library10.1074/jbc.m710140200

15. 15.

    Smerdel-Ramoya A, Zanotti S, Stadmeyer L, Durant D, Canalis E. Skeletal overexpression of connective tissue growth factor impairs bone formation and causes osteopenia. Endocrinology. 2008;149:4374-4381.

    Not in our library10.1210/en.2008-0254

16. 16.

    Rydziel S, Stadmeyer L, Zanotti S, Durant D, Smerdel-Ramoya A, Canalis E. Nephroblastoma overexpressed (Nov) inhibits osteoblastogenesis and causes osteopenia. J Biol Chem. 2007;282:19762-19772.

    Not in our library10.1074/jbc.m700212200

17. 17.

    Heath E, Tahri D, Andermarcher E, Schofield P, Fleming S, Boulter CA. Abnormal skeletal and cardiac development, cardiomyopathy, muscle atrophy and cataracts in mice with a targeted disruption of the Nov (Ccn3) gene. BMC Dev Biol. 2008;8:18.

    Not in our library10.1186/1471-213x-8-18

18. 18.

    Ivkovic S, Yoon BS, Popoff SN, et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development. 2003;130:2779-2791.

    Not in our library10.1242/dev.00505

19. 19.

    Arnott JA, Zhang X, Sanjay A, et al. Molecular requirements for induction of CTGF expression by TGF-beta1 in primary osteoblasts. Bone. 2008;42:871-885.

    Not in our library10.1016/j.bone.2008.01.006

20. 20.

    Konigshoff M, Kramer M, Balsara N, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest. 2009;119:772-787.

    Not in our library10.1172/jci33950

21. 21.

    Shimo T, Kubota S, Yoshioka N, et al. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res. 2006;21:1045-1059.

    Not in our library10.1359/jbmr.060416

22. 22.

    Kleer CG, Zhang Y, Merajver SD. CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer. Cells Tissues Organs. 2007;185:95-99.

    Not in our library10.1159/000101308

23. 23.

    Bennewith KL, Huang X, Ham CM, et al. The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 2009;69:775-784.

    Not in our library10.1158/0008-5472.can-08-0987

24. 24.

    Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005;65:8887-8895.

    Not in our library10.1158/0008-5472.can-05-1702

25. 25.

    Maillard M, Cadot B, Ball RY, et al. Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol. 2001;54:275-280.

    Not in our library10.1136/mp.54.4.275

26. 26.

    Tanaka S, Sugimachi K, Saeki H, et al. A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene. 2001;20:5525-5532.

    Not in our library10.1038/sj.onc.1204723

27. 27.

    Kidd M, Modlin IM, Eick GN, Camp RL, Mane SM. Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. Am J Physiol Gastrointest Liver Physiol. 2007;292:G191-200.

    Not in our library10.1152/ajpgi.00131.2006

28. 28.

    Kawaki H, Kubota S, Suzuki A, et al. Functional requirement of CCN2 for intramembranous bone formation in embryonic mice. Biochem Biophys Res Commun. 2008;366:450-456.

    Not in our library10.1016/j.bbrc.2007.11.155

29. 29.

    Kubota S, Takigawa M. CCN family proteins and angiogenesis: from embryo to adulthood. Angiogenesis. 2007;10:1-11.

    Not in our library10.1007/s10456-006-9058-5

30. 30.

    Colston JT, de la Rosa SD, Koehler M, et al. Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor. Am J Physiol Heart Circ Physiol. 2007;293:H1839-1846.

    Not in our library10.1152/ajpheart.00428.2007

31. 31.

    Leu SJ, Lam SC, Lau LF. Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem. 2002;277:46248-46255.

    Not in our library10.1074/jbc.m209288200

32. 32.

    Lin CG, Leu SJ, Chen N, et al. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J Biol Chem. 2003;278:24200-24208.

    Not in our library10.1074/jbc.m302028200

33. 33.

    Lin CG, Chen CC, Leu SJ, Grzeszkiewicz TM, Lau LF. Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing. J Biol Chem. 2005;280:8229-8237.

    Not in our library10.1074/jbc.m404903200

34. 34.

    Vallacchi V, Daniotti M, Ratti F, et al. CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res. 2008;68:715-723.

    Not in our library10.1158/0008-5472.can-07-2103

35. 35.

    Crockett JC, Schutze N, Tosh D, et al. The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5. Endocrinology. 2007;148:5761-5768.

    Not in our library10.1210/en.2007-0473

36. 36.

    Hoshijima M, Hattori T, Inoue M, et al. CT domain of CCN2/CTGF directly interacts with fibronectin and enhances cell adhesion of chondrocytes through integrin alpha5beta1. FEBS Lett. 2006;580:1376-1382.

    Not in our library10.1016/j.febslet.2006.01.061

37. 37.

    Benini S, Perbal B, Zambelli D, et al. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene. 2005;24:4349-4361.

    Not in our library10.1038/sj.onc.1208620

38. 38.

    Xie D, Yin D, Tong X, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res. 2004;64:1987-1996.

    Not in our library10.1158/0008-5472.can-03-0666

39. 39.

    Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol. 2002;4:599-604.

    Not in our library10.1038/ncb826

40. 40.

    Nakamura Y, Weidinger G, Liang JO, et al. The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signaling. J Clin Invest. 2007;117:3075-3086.

    Not in our library10.1172/jci32001

Cited by papers we hold 4

• Systematic Analysis of mRNAs and ncRNAs in BMSCs of Senile Osteoporosis Patients · 2021
  Not checked
• Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases · 2020
  No notice
• Fibro–Adipogenic Progenitors Cross-Talk in Skeletal Muscle: The Social Network · 2019
  No notice
• Regulatory Effects and Interactions of the Wnt and OPG-RANKL-RANK Signaling at the Bone-Cartilage Interface in Osteoarthritis · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.